Tvardi Therapeutics
TVRD
49 hedge funds and large institutions have $149M invested in Tvardi Therapeutics in 2014 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
17% more funds holding
Funds holding: 42 → 49 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less capital invested
Capital invested by funds: $160M → $149M (-$11.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Aberdeen Asset Management
Aberdeen,
United Kingdom
|
+$13.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.18M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.08M |
| 4 |
TA
Teachers Advisors
New York
|
+$1.58M |
| 5 |
State Street
Boston,
Massachusetts
|
+$920K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LBG
Lloyds Banking Group
London,
United Kingdom
|
-$16.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.17M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$1.9M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$1.74M |
| 5 |
Jennison Associates
New York
|
-$1.03M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EMFAT
51
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
| – | -$1.9M | -2,841 | Closed |
|
|
EA
52
Emerald Advisers
Leola,
Pennsylvania
| – | -$1.74M | -2,592 | Closed |
|
|
CBOA
53
Commonwealth Bank of Australia
Sydney, NSW,
Australia
| – | -$521K | -778 | Closed |
|
|
EEG
54
E.E. Geduld
| – | -$242K | -361 | Closed |
|
55
Jane Street
New York
| – | -$230K | -343 | Closed |
|
|
SCA
56
SAC Capital Advisors
Stamford,
Connecticut
| – | -$208K | -310 | Closed |
|
|
TRCT
57
Tower Research Capital (TRC)
New York
| – | -$68K | -102 | Closed |
|
TVRD Hedge Fund Activity: Q2 2014 in Review
49 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2014, worth a combined $149M — down 6.9% from $160M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TVRD positions and 8 closed out — a net gain of 7 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Aberdeen Asset Management, opening a new position worth an estimated $13.3M. The largest seller was Lloyds Banking Group, exiting entirely with an estimated $16.6M sold.
- 49 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2014, up from 42 in Q1 2014.
- Funds reported $149M of Tvardi Therapeutics stock for Q2 2014, down 6.9% quarter-over-quarter.
- 15 funds opened new Tvardi Therapeutics positions in Q2 2014 and 8 closed out, a net change of +7 holders.
- The largest Tvardi Therapeutics buyer in Q2 2014 was Aberdeen Asset Management, an estimated $13.3M added.
- The largest Tvardi Therapeutics seller in Q2 2014 was Lloyds Banking Group, an estimated $16.6M sold.
Based on aggregated 13F filings for Q2 2014.